A Phase 2 Study of Inotuzumab Ozogamicin in Children and Young Adults with Relapsed or Refractory CD22+ B-Acute Lymphoblastic Leukemia (B-ALL), COG ID AALL1621/Pfizer No. WI221468
|Effective start/end date
|4/1/22 → 3/31/25
- PUBLIC HEALTH INSTITUTE
- PFIZER, INC.
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.